Trial Profile
Autologous Bone Marrow Derived Cell Transplant in Spinal Cord Injury Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Feb 2016
Price :
$35
*
At a glance
- Drugs Autologous bone marrow derived mesenchymal stem cell therapy-Celvive (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions
- 04 Feb 2016 New trial record